Date: November 9, 2022 Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CET)

How to improve patient management with molecular solutions for cervical cancer screening and CIN2/3 diagnosed women

Sponsored by: QIAGEN

Date:  November 9, 2022
Time: 3:00am (PDT),  6:00am (EDT), 12:00pm (CET)
An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organized screening because of better clinical performance. HPV assays need to be clinically validated and comply with international guidelines to assure high quality of primary HPV-based screening. Nevertheless screening also results in considerable overtreatment because many CIN2/3 lesions show spontaneous regression so a triage strategy is necessary and methylation can be used to support a wait-and-see policy in women with CIN2/3. The webinar brings recent study data about the fully automated clinically approved NeuMoDx HPV Test Strip screening test and the prognostic value of FAM19A4/miR124-2 methylation to support conservative management of CIN2+ diagnosed women.
Webinars will be available for unlimited on-demand viewing after live event.

Show Resources
You May Also Like
Loading Comments...
Show Resources